OTTAWA, Sept. 2 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF)
("PharmaGap" or "the Company") today announced that results are expected
during September from the United States National Cancer Institute (NCI)
follow-up study of the company's lead drug GAP-107B8.
Results from the initial NCI single dose study released on August 24
showed greater than 50% effect of GAP-107B8 in reduction of cancer cell growth
in 26 of the 57 human cancer cell lines tested. Compelling results were found
in all 9 cancer types tested, with very positive results in melanoma, breast,
central nervous system, and prostate cancers.
The initial test used a single low dose (10(micro)M) to evaluate the
effect of GAP-107B8 against the 57 cancer cell lines in the test. In specific
melanoma, breast, central nervous system, and prostate cancer cell lines,
growth inhibition of 100% was observed (the announcement of results can be
found on the Company's website www.pharmagap.com).
Following these compelling results in the initial one-dose testing
protocol, GAP-107B8 was selected for testing by the NCI in the same NCI-60
tumour cell panel using five dose concentrations. This range of doses is
intended to further examine the drug's effectiveness in human cancer tumour
cells, to allow further characterization of the drug's activity against
various cancer types, and to provide insight into its method of action.
The NCI-60 protocol tests a wide variety of cancers, including breast,
colorectal, lung, ovarian, kidney, prostate, leukemia and various central
nervous system cancers and melanomas.
About The National Cancer Institute
The National Cancer Institute (NCI), located in Bethesda, MD is an
institute of the National Institutes of Health, the primary U.S. Federal
Agency for conducting and supporting medical research. The NCI has a mandate
to select and screen novel drug compounds that could potentially make a
material difference in the "war against cancer". Selection to the NCI
screening program is through a competitive application process. Details on the
NCI's compound screening program can be found at http://dtp.nci.nih.gov/. More
general information on the NCI is found at www.cancer.gov.
About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF), based in Ottawa, ON, is a
biotechnology company with a core focus on developing novel peptide
therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel
peptide drug designed to inhibit the activity of protein kinase C (PKC), a
cell signalling enzyme implicated in certain types and stages of cancer.
Independent peer-reviewed research has demonstrated that over-expression of
PKC plays a role in the development of many cancer types. For more information
please visit www.pharmagap.com.
Note: Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release. No
Securities Commission or other regulatory authority having jurisdiction over
PharmaGap has approved or disapproved of the information contained herein.
This release contains forward looking statements that may not occur or may
For further information:
For further information: relating to this Release, please contact:
Robert McInnis, President & CEO, (613) 990-9551, firstname.lastname@example.org